NEW YORK, December 10, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Amgen, Inc. (NASDAQ: AMGN), Puma Biotechnology Inc. (NYSE: PBYI), Abbott Laboratories (NYSE: ABT) and Agilent Technologies Inc. (NYSE: A). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pfizer Inc. Research Report
On December 4, 2013, Pfizer Inc. (Pfizer) announced an update of its clinical data access policy that will simplify and broaden access to information gathered in Pfizer-sponsored clinical trials. According to Pfizer, the updated policy meets or exceeds the "Principles of Responsible Data Sharing" issued by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in July 2013. Pfizer said that the updated policy builds upon and expands the Company's established methods of clinical trial information sharing, including Pfizer's long track record of submitting for publication results from all interventional clinical trials in patients and its pioneering efforts to provide clinical trial results and data to study participants. In addition, the Company stated that its expanded clinical data access policy also reinforces its current practice of submitting for publication manuscripts for all interventional clinical trials in patients, regardless of outcomes, within 18 months of study completion, and Pfizer's commitment to register and post summary results for interventional human clinical trials to clinicaltrials.gov in the United States and to registries outside the United States, as required. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Amgen, Inc. Research Report
On December 5, 2013 Amgen, Inc.'s (Amgen) stock rose 0.25%, ending the day at $113.35. Over the previous three trading sessions, shares of Amgen declined 0.98% compared to the Nasdaq Composite which declined 0.30% during the same period. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Puma Biotechnology Inc. Research Report
On December 4, 2013, Puma Biotechnology, Inc. (Puma Bio) announced top line results from the Phase II clinical trial of Puma's investigational drug (PB272) neratinib for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL). According to the Company, the I-SPY 2 TRIAL is a randomized Phase II clinical trial for women with newly diagnosed Stage 2 or higher (tumor size at least 2.5 cm) breast cancer that addresses whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy. Puma Bio stated that the goal of the trial is to match investigational regimens with patient subsets on the basis of molecular characteristics (biomarker signatures) that benefit from the regimen. The Company also revealed that the neratinib-containing regimen graduated from the I-SPY 2 TRIAL based on having a high probability of success in Phase III with a signature of HER2-positive/HR-negative. It further added that in this group, treatment with the neratinib-containing regimen resulted in a higher pCR rate compared to the control arm (standard neoadjuvant chemotherapy: paclitaxel in combination with Herceptin (trastuzumab), followed by doxorubicin and cyclophosphamide). The Full Research Report on Puma Biotechnology Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Abbott Laboratories Research Report
On December 5, 2013, Abbott Laboratories' (Abbott) stock declined 1.18%, ending the day at $36.92. Over the previous three trading sessions, shares of Abbott declined 3.20% compared to the S&P 500 which declined 0.88% during the same period. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Agilent Technologies Inc. Research Report
On December 4, 2013, Agilent Technologies Inc. (Agilent) expanded its range of signal generators with two new models: N5183B MXG and N5173B EXG. According to the Company, these new microwave analog signal generators provide unmatched performance in phase noise, output power and frequency-switching speed. Agilent stated that the N5183B MXG analog is an alternative to the high performance PSG, and offers accuracy, efficiency, and near-PSG performance in only two rack units. In addition, Agilent stated that the N5173B EXG analog is a cost-effective option when system creators need to balance budget and performance, and offers the best combination of output power (+20 dBm at 20 GHz) and low harmonics (<-55 dBc), making it well-suited to the characterization of broadband microwave components such as filters and amplifiers. The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner